Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05JHA
|
||||
| Former ID |
DNC013436
|
||||
| Drug Name |
H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H31N7O8S2
|
||||
| Canonical SMILES |
C1C(C(=O)NCC(=O)NC(C(=O)NC(CSS1)C(=O)N)CC2=CC=C(C=C2)[N<br />+](=O)[O-])NC(=O)C(CC3=CC=C(C=C3)O)N
|
||||
| InChI |
1S/C26H31N7O8S2/c27-18(9-14-3-7-17(34)8-4-14)24(37)32-21-13-43-42-12-20(23(28)36)31-26(39)19(30-22(35)11-29-25(21)38)10-15-1-5-16(6-2-15)33(40)41/h1-8,18-21,34H,9-13,27H2,(H2,28,36)(H,29,38)(H,30,35)(H,31,39)(H,32,37)/t18-,19-,20-,21-/m0/s1
|
||||
| InChIKey |
NBZQMFLIMSGMAF-TUFLPTIASA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Delta-type opioid receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Opioid proenkephalin pathway | |||||
| Opioid proopiomelanocortin pathway | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.